PIPAC versus HIPEC: cisplatin spatial distribution and diffusion in a swine model

References

• Elias D, Goéré D, Dumont F, et al. Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases. Eur J Cancer. 2014;50(2):332–340.
   PubMed Web of Science ®Google Scholar
• Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426–2432.
   PubMed Web of Science ®Google Scholar
• van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230–240.
   PubMed Web of Science ®Google Scholar
• Rihuete-Caro C, Manzanedo I, Pereira F, et al. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with gastric cancer and peritoneal carcinomatosis. Eur J Surg Oncol. 2018;44(11):1805–1810.
   PubMed Web of Science ®Google Scholar
• Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016;17(12):1709–1719.
   PubMed Web of Science ®Google Scholar
• Wagner AD, Syn NL, Moehler M, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8:CD004064.
   PubMed Web of Science ®Google Scholar
• Miura JT, Johnston FM, Gamblin TC, et al. Current trends in the management of malignant peritoneal mesothelioma. Ann Surg Oncol. 2014;21(12):3947–3953.
   PubMed Web of Science ®Google Scholar
• Dedrick RL, Myers CE, Bungay PM, et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62(1):1–11.
   PubMedGoogle Scholar
• Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst. 1997;89(7):480–487.
   PubMed Web of Science ®Google Scholar
• Solass W, Kerb R, Mürdter T, et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol. 2014;21(2):553–559.
   PubMed Web of Science ®Google Scholar
• Solaß W, Hetzel A, Nadiradze G, et al. Description of a novel approach for intraperitoneal drug delivery and the related device. Surg Endosc. 2012;26(7):1849–1855.
   PubMed Web of Science ®Google Scholar
• Khosrawipour V, Khosrawipour T, Kern AJP, et al. Distribution pattern and penetration depth of doxorubicin after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a postmortem swine model. J Cancer Res Clin Oncol. 2016;142(11):2275–2280.
   PubMed Web of Science ®Google Scholar
• Di Giorgio A, De Iaco P, De Simone M, et al. Cytoreduction (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced ovarian cancer: retrospective italian multicenter observational study of 511 cases. Ann Surg Oncol. 2017;24(4):914–922.
   PubMed Web of Science ®Google Scholar
• Tempfer CB, Celik I, Solass W, et al. Activity of pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in women with recurrent, platinum-resistant ovarian cancer: preliminary clinical experience. Gynecol Oncol. 2014;132(2):307–311.
   PubMed Web of Science ®Google Scholar
• Los G, Sminia P, Wondergem J, et al. Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats. Eur J Cancer. 1991;27(4):472–477.
   PubMed Web of Science ®Google Scholar
• Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–374.
   PubMedGoogle Scholar
• Reymond MA, Hu B, Garcia A, et al. Feasibility of therapeutic pneumoperitoneum in a large animal model using a microvaporisator. Surg Endosc. 2000;14(1):51–55.
   PubMed Web of Science ®Google Scholar
• Solass W, Herbette A, Schwarz T, et al. Therapeutic approach of human peritoneal carcinomatosis with Dbait in combination with capnoperitoneum: proof of concept. Surg Endosc . 2012;26(3):847–852.
   PubMed Web of Science ®Google Scholar
• Khosrawipour V, Khosrawipour T, Falkenstein TA, et al. Evaluating the effect of Micropump© position, internal pressure and doxorubicin dosage on efficacy of pressurized intra-peritoneal aerosol chemotherapy (PIPAC) in an ex vivo model. Anticancer Res. 2016;36(9):4595–4600.
   PubMed Web of Science ®Google Scholar
• Bellendorf A, Khosrawipour V, Khosrawipour T, et al. Scintigraphic peritoneography reveals a non-uniform 99mTc-pertechnetat aerosol distribution pattern for pressurized intra-peritoneal aerosol chemotherapy (PIPAC) in a swine model. Surg Endosc. 2017; 26(4):1849–1849.
   Google Scholar
• Göhler D, Khosrawipour V, Khosrawipour T, et al. Technical description of the microinjection pump (MIP®) and granulometric characterization of the aerosol applied for pressurized intraperitoneal aerosol chemotherapy (PIPAC). Surg Endosc. 2017;31(4):1778–1784.
   PubMed Web of Science ®Google Scholar
• Reymond MA, Solass W. PIPAC: pressurized intraperitoneal aerosol chemotherapy–cancer under pressure. 2014.
   Google Scholar
• Khosrawipour V, Giger-Pabst U, Khosrawipour T, et al. Effect of irradiation on tissue penetration depth of doxorubicin after pressurized intra-peritoneal aerosol chemotherapy (PIPAC) in a novel ex-vivo model. J Cancer. 2016;7(8):910–914.
   PubMed Web of Science ®Google Scholar
• Khosrawipour V, Khosrawipour T, Hedayat-Pour Y, et al. Effect of whole-abdominal irradiation on penetration depth of doxorubicin in normal tissue after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a post-mortem swine model. Anticancer Res Int Inst Anticancer Res. 2017;37(4):1677–1680.
   PubMed Web of Science ®Google Scholar
• Kakchekeeva T, Demtröder C, Herath NI, et al. In vivo feasibility of electrostatic precipitation as an adjunct to pressurized intraperitoneal aerosol chemotherapy (ePIPAC). Ann Surg Oncol. 2016;23(S5):592–598.
   PubMed Web of Science ®Google Scholar
• Khosrawipour V, Mikolajczyk A, Schubert J, et al. Pressurized intra-peritoneal aerosol chemotherapy (PIPAC) via endoscopical microcatheter system. Anticancer Res. 2018;38(6):3447–3452.
   PubMed Web of Science ®Google Scholar
• Willaert W, Van de Sande L, Van Daele E, et al. Safety and preliminary efficacy of electrostatic precipitation during pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable carcinomatosis. Eur J Surg Oncol. 2019;45(12):2302–2309.
   PubMed Web of Science ®Google Scholar
• Göhler D, Große S, Bellendorf A, et al. Hyperthermic intracavitary nanoaerosol therapy (HINAT) as an improved approach for pressurised intraperitoneal aerosol chemotherapy (PIPAC): technical description, experimental validation and first proof of concept. Beilstein J Nanotechnol. 2017;8:2729–2740.
   PubMed Web of Science ®Google Scholar
• Tempfer CB, Giger-Pabst U, Seebacher V, et al. A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis. Gynecol Oncol. 2018;50(1):23–30.
   Web of Science ®Google Scholar
• Robella M, Vaira M, De Simone M. Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis. World J Surg Onc. 2016;14(1):128.
   PubMed Web of Science ®Google Scholar
• Gouy S, Ferron G, Glehen O, et al. Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer. Gynecol Oncol. 2016;142(2):237–242.
   PubMed Web of Science ®Google Scholar
• Blanco A, Giger-Pabst U, Solass W, et al. Renal and hepatic toxicities after pressurized intraperitoneal aerosol chemotherapy (PIPAC). Ann Surg Oncol. 2013;20(7):2311–2316.
   PubMed Web of Science ®Google Scholar
• Howell SB, Pfeifle CE, Wung WE, et al. Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res. 1983;43(3):1426–1431.
   PubMed Web of Science ®Google Scholar
• Hanada K, Nishijima K, Ogata H, et al. Population pharmacokinetic analysis of cisplatin and its metabolites in cancer patients: possible misinterpretation of covariates for pharmacokinetic parameters calculated from the concentrations of unchanged cisplatin, ultrafiltered platinum and total platinum. Jpn J Clin Oncol. 2001;31(5):179–184.
   PubMed Web of Science ®Google Scholar
• Reece PA, Stafford I, Russell J, et al. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol. 1987;5(2):304–309.
   PubMed Web of Science ®Google Scholar
• Nagai N, Kinoshita M, Ogata H, et al. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients. Cancer Chemother Pharmacol. 1996;39(1–2):131–137.
   PubMed Web of Science ®Google Scholar
• Nagai N, Ogata H, Wada Y, et al. Population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: analysis with the NONMEM program. J Clin Pharmacol. 1998;38(11):1025–1034.
   PubMed Web of Science ®Google Scholar
• Urien S, Brain E, Bugat R, et al. Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients. Cancer Chemother Pharmacol. 2005;55(1):55–60.
   PubMed Web of Science ®Google Scholar
• Los G, Mutsaers PHA, van der Vijgh WJF, et al. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitonal chemotherapy: a comparison with systemic chemotherapy. Cancer Res Am Assoc Cancer Res. 1989;49(12):3380–3384.
   PubMed Web of Science ®Google Scholar
• van de Vaart PJM, van der Vange N, Zoetmulder FAN, et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin–DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer. 1998;34(1):148–154.
   PubMed Web of Science ®Google Scholar